Global pharmaceutical companies are entering 2026 facing a high-stakes European drug pricing dispute as they seek to offset recent price concessions in the United States. Following intense pressure from President Donald Trump, who secured major drug price cuts for American patients in late 2025, companies are now turning to Europe to recoup revenue losses. Manufacturers such as Pfizer, Eli Lilly, and AstraZeneca have…